Everus Construction Group, Inc.
ECG
$151.02
-9.00%
Everus Construction Group, Inc. is a construction solutions provider offering specialty contracting services, primarily in electrical, mechanical, and transmission & distribution systems, across public and private sectors in the U.S. The company operates as a significant player in the Engineering & Construction industry, distinguishing itself through its dual-segment focus that diversifies its revenue streams across utility and commercial end markets. The current investor narrative is heavily influenced by the company's explosive stock price performance and robust revenue growth, likely driven by strong demand for infrastructure and energy transition projects, though this rapid ascent has also introduced debates about valuation sustainability and potential overextension.…
ECG
Everus Construction Group, Inc.
$151.02
Investment Opinion: Should I buy ECG Today?
Rating & Thesis: Hold. ECG is a high-quality growth story with exceptional fundamentals, but its valuation has run ahead of even optimistic projections after a 164% surge, creating asymmetric risk/reward at current levels. The mixed analyst sentiment (Stifel Buy, DA Davidson Neutral) and lack of a broad consensus target reflect this uncertainty.
Supporting Evidence: The valuation is stretched, with a forward PE of 30.88x far exceeding the trailing PE of 21.65x. While revenue growth is robust at 33% YoY and profitability is expanding (net margin up 93 bps YoY), the stock trades at 92% of its 52-week high, suggesting limited near-term upside before technical resistance. The PEG ratio of 0.54 appears attractive but is backward-looking; sustaining that growth to justify the forward multiple is the critical challenge. Positive free cash flow of $90M TTM supports the fundamental quality, but does not justify the current premium alone.
Risks & Conditions: The two biggest risks are growth deceleration and multiple compression. This Hold would upgrade to a Buy if the stock corrects to a forward PE below 22x (approximately $112-$115) or if next-quarter revenue growth accelerates above 35% while maintaining margins. It would downgrade to a Sell if quarterly revenue growth decelerates below 20% or if the forward PE expands above 35x without corresponding earnings beats. Relative to its own history and growth trajectory, the stock is currently overvalued, pricing in perfection.
Sign up to view all
ECG 12-Month Price Forecast
ECG is a fundamentally strong company caught in a valuation trap. The explosive revenue growth and high ROE justify investor enthusiasm, but the 164% price surge over the past year has likely front-run much of the near-term optimism. The forward PE of 30.88x demands flawless execution and sustained hyper-growth, a scenario with a low probability. The base case of consolidation and multiple compression is most likely. The stance would upgrade to bullish on a significant pullback (below $130) that improves the risk/reward, or on clear evidence of accelerating growth. It would turn bearish if quarterly revenue growth dips below 20%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Everus Construction Group, Inc.'s 12-month outlook, with a consensus price target around $196.33 and implied upside of +30.0% versus the current price.
Average Target
$196.33
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$121 - $196
Analyst target range
Analyst coverage for ECG appears limited, with data indicating only one analyst providing estimates, which suggests the stock may have minimal institutional coverage typical of a smaller or recently listed company. The single analyst estimates an average EPS of $7.26 for the upcoming period on revenue of $6.188 billion. Without a consensus price target or a clear Buy/Hold/Sell distribution from the provided data, it is challenging to gauge directional sentiment, though recent institutional ratings show a mix of 'Buy' and 'Neutral' actions. The target price range is not explicitly provided in the data, but the estimated EPS range is $7.03 (low) to $7.53 (high). The wide implied revenue estimate range of $6.035 billion to $6.366 billion signals some uncertainty in forward projections. Recent rating actions from firms like Stifel (maintaining Buy) and DA Davidson (maintaining Neutral) indicate stable but not uniformly bullish sentiment. The lack of a broad analyst consensus and price targets implies higher volatility and less efficient price discovery, as the stock's valuation is driven more by market momentum and direct investor interpretation of fundamentals than by institutional research anchoring.
Bulls vs Bears: ECG Investment Factors
The bull case, supported by explosive 33% revenue growth, expanding profitability, and strong cash flow, currently holds stronger evidence. However, the bear case presents a formidable counter-argument centered on valuation sustainability after a 164% price surge. The single most important tension in the investment debate is whether ECG's current 33% revenue growth rate can be maintained to justify its forward PE of 30.88x. If growth persists, the attractive PEG ratio of 0.54 suggests further upside. If growth decelerates even moderately, the stretched forward multiple creates significant downside risk from current levels.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 33.15% year-over-year to $1.011 billion, demonstrating powerful demand momentum. Sequential quarterly revenue has climbed consistently from $826.6M in Q1 to over $1B in Q4, indicating the growth is broad-based and sustainable.
- Strong Profitability & Expanding Margins: Net income grew 60% YoY in Q4 to $55.28M, with net margin expanding from 4.54% to 5.47%. The company's trailing ROE of 32.04% and ROA of 11.37% are exceptionally high for the industrials sector, indicating efficient capital deployment.
- Robust Balance Sheet & Cash Flow: The company has a healthy current ratio of 1.76 and a manageable debt-to-equity of 0.59. It generates significant free cash flow ($90.01M TTM), providing financial flexibility to fund operations and growth internally without excessive leverage.
- Attractive PEG Ratio: With a trailing PE of 21.65x and 33% revenue growth, the PEG ratio is 0.54. This suggests the stock may be undervalued relative to its growth rate if that growth is sustainable, a key point of debate.
Bearish
- Valuation Stretched on Forward Basis: The forward PE of 30.88x is significantly higher than the trailing PE of 21.65x, indicating the market is pricing in aggressive future earnings growth. The current trailing PE is also near the high end of its own historical range (12.9x-24.3x), suggesting limited multiple expansion potential.
- High Volatility & Technical Overextension: The stock's 1-year relative strength of 138.78% vs. SPY confirms extreme volatility. Trading at 92% of its 52-week high after a 164% surge increases vulnerability to profit-taking, as evidenced by a recent maximum drawdown of -20.26%.
- Limited Analyst Coverage & High Uncertainty: Only one analyst provides estimates, indicating minimal institutional research and potentially inefficient price discovery. The wide revenue estimate range ($6.035B-$6.366B) signals significant uncertainty in forward projections, increasing stock-specific risk.
- Potential Growth Deceleration Risk: While current growth is strong, the forward PE of 30.88x implies the market expects continued high growth. Any deceleration from the current 33% YoY pace could trigger severe multiple compression, given the premium valuation.
ECG Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 163.77% gain over the past year. With a current price of $157.71, it is trading near the top of its 52-week range (high: $171.58, low: $58.08), specifically at approximately 92% of that range, indicating strong momentum but also positioning it near potential technical resistance where profit-taking could emerge. Recent momentum remains robust but shows signs of consolidation; the stock is up 7.83% over the past month and 42.15% over the past three months, which, while positive, represents a deceleration from the torrid 1-year pace, suggesting the trend may be maturing and entering a volatile consolidation phase. Short-term momentum has been volatile, with the 1-month return of 7.83% underperforming the 3-month return of 42.15%, indicating recent choppiness. This divergence from the longer-term parabolic rise could signal a healthy consolidation or a pause as the stock digests its massive gains, with key support at the 52-week low of $58.08 now far below. The stock's implied volatility is high, as suggested by a maximum drawdown of -20.26% within the provided period, underscoring its sensitivity to market sentiment shifts. Key technical levels are clear: immediate resistance is at the 52-week high of $171.58, while major support rests at the 52-week low of $58.08. A decisive breakout above $171.58 would signal a continuation of the bullish trend, whereas a sustained move below recent consolidation lows could indicate a deeper correction. The stock's beta is not explicitly provided, but its 1-year relative strength of 138.78% versus the SPY's 24.99% gain confirms it has been dramatically more volatile and momentum-driven than the broader market, a critical factor for risk-aware investors.
Beta
—
—
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$62-$172
Price range past year
Annual Return
+140.4%
Cumulative gain past year
| Period | ECG Return | S&P 500 |
|---|---|---|
| 1m | +4.1% | -1.7% |
| 3m | +21.9% | +13.7% |
| 6m | +69.3% | +9.2% |
| 1y | +140.4% | +20.7% |
| ytd | +69.3% | +9.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ECG Fundamental Analysis
Revenue growth is exceptionally strong and accelerating. For Q4 2025, revenue reached $1.011 billion, representing a year-over-year growth rate of 33.15%. This follows a sequential pattern of increasing quarterly revenues from $826.6M in Q1 2025 to $1.011B in Q4 2025, indicating sustained demand momentum. Segment data shows the Electrical & Mechanical segment generated $407.97 million in a recent period, significantly larger than the Transmission & Distribution segment's $113.28 million, making E&M the primary growth driver. The company is profitable with expanding margins. Q4 2025 net income was $55.28 million, yielding a net margin of 5.47%. Gross margin for the quarter was 11.62%, while the trailing twelve-month net margin stands at 5.39%. Profitability has improved year-over-year, as Q4 2024 net income was $34.47 million with a gross margin of 11.36%, demonstrating margin expansion. The operating margin for the latest quarter was 6.81%, indicating efficient cost control relative to revenue scale. Balance sheet health is solid, with a strong current ratio of 1.76 and a manageable debt-to-equity ratio of 0.59. The company generates substantial cash flow, with trailing twelve-month free cash flow of $90.01 million and an operating cash flow of $48.21 million for Q4 2025. Return on Equity is robust at 32.04%, and Return on Assets is healthy at 11.37%. The positive free cash flow of $90.01 million against a market cap of ~$4.37 billion implies the company can internally fund operations and growth, reducing financial risk.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.33%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$90009000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ECG Overvalued?
Given a positive net income of $55.28 million for Q4 2025, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 21.65x, while the forward PE is significantly higher at 30.88x. This substantial gap suggests the market is pricing in a deceleration in earnings growth or has elevated expectations for future profitability that are not yet reflected in trailing results. Compared to industry averages, the stock trades at a premium based on its sales multiple. Its Price-to-Sales ratio of 1.17x and EV-to-Sales of 1.99x are not directly comparable without a provided industry average, but the EV-to-EBITDA of 14.09x offers a profitability-based comparison. The PEG ratio of 0.54, based on trailing metrics, suggests the stock may be undervalued relative to its growth rate if that growth is sustainable, a key point of debate. Historically, the stock's current trailing PE of 21.65x sits above its recent historical range observed in the data, which has fluctuated between approximately 12.9x and 24.3x over the past two years. This places it near the higher end of its own historical valuation band, indicating the market is currently pricing in optimistic expectations. Trading near historical highs increases sensitivity to any earnings disappointment or growth deceleration.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ECG's primary financial risk is valuation compression if growth decelerates. The forward PE of 30.88x implies extremely high expectations; a slowdown from the current 33% revenue growth could trigger severe multiple contraction. While the balance sheet is solid (D/E 0.59), the company operates on thin gross margins (11.62%), making it vulnerable to cost inflation in labor and materials that could pressure the already modest 5.47% net margin. Revenue concentration in the Electrical & Mechanical segment ($408M vs. $113M for T&D) creates some diversification risk, though both segments benefit from infrastructure tailwinds.
Market & Competitive Risks: The stock trades at a significant premium to its own historical valuation, with a trailing PE of 21.65x near the top of its 2-year range (12.9x-24.3x). This leaves it exposed to sector rotation out of high-momentum industrials if macroeconomic conditions weaken. The stock's extreme volatility (138.78% relative strength vs. SPY) and high short ratio (2.54) indicate it is a battleground stock, prone to sharp swings on sentiment. Limited analyst coverage (one analyst) reduces institutional anchoring and increases the potential for exaggerated moves on company-specific news.
Worst-Case Scenario: The worst-case scenario involves a simultaneous growth deceleration and multiple compression. If quarterly revenue growth slows to mid-single digits and the forward PE contracts toward 15x (still above industry average but below historical mid-point), the stock could revisit its 52-week low of $58.08. This represents a catastrophic -63% decline from the current $157.71. A more realistic adverse scenario, involving a mild recession impacting construction spending, could see a -35% to -40% correction toward the $95-$100 range, aligning with previous consolidation levels and representing a maximum drawdown consistent with its -20.26% recent volatility.
FAQ
The key risks are, in order of severity: 1) Valuation & Growth Deceleration Risk: The forward PE of 30.88x is highly vulnerable if revenue growth slows from 33%. 2) Volatility & Technical Risk: The stock is up 164% in a year and is prone to sharp corrections, with a recent max drawdown of -20.26%. 3) Market & Sentiment Risk: Limited analyst coverage (one analyst) and a high short ratio (2.54) can lead to exaggerated price swings on news. 4) Operational Risk: Thin gross margins (11.62%) expose profits to cost inflation in a competitive contracting environment.
The 12-month forecast presents three scenarios. The Bull Case (25% probability) targets $172-$190, requiring sustained >30% growth and a breakout above the 52-week high. The Base Case (55% probability) targets $130-$150, assuming growth moderates to 20-25% and the forward PE compresses. The Bear Case (20% probability) targets $85-$110, triggered by a sharp growth slowdown. The Base Case is most likely, centered on the analyst's average EPS estimate of $7.26 and a valuation multiple cooling from current extremes. The key assumption is that growth decelerates but remains robust, preventing a full derating.
ECG is overvalued relative to its own history and current growth expectations. The trailing PE of 21.65x is near the top of its 2-year range (12.9x-24.3x). More critically, the forward PE of 30.88x implies the market expects significant earnings acceleration. While the backward-looking PEG ratio of 0.54 seems cheap, it is based on past hyper-growth. The current valuation implies the market expects near-perfect execution and sustained growth rates above 30%, leaving little room for error. Compared to industrials peers, it trades at a premium justified only if its superior growth persists.
ECG is a good buy only for aggressive investors who can tolerate high volatility and are buying on a significant pullback. At the current price of $157.71, the risk/reward is unfavorable due to the stretched forward PE of 30.88x and the stock trading at 92% of its 52-week high after a 164% rally. The biggest downside risk is growth deceleration triggering multiple compression. For most investors, it is prudent to wait for a better entry point below $130, where the valuation better reflects the company's still-strong but moderating growth profile.
ECG is more suitable for a medium-term investment horizon of 1-3 years rather than short-term trading or long-term buy-and-hold. Its high beta and momentum-driven price action make it risky for short-term traders without strict risk controls. For long-term investors, the current valuation presents a poor entry point that could require years to grow into. The ideal holding period aligns with the cycle of infrastructure spending, allowing the company to execute on its backlog and prove its growth sustainability, while navigating the inevitable volatility. A minimum holding period of 18-24 months is suggested to ride out potential volatility.